

Lars Bastholt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/228943/publications.pdf>

Version: 2024-02-01

125
papers

21,989
citations

53794

45
h-index

16650

123
g-index

127
all docs

127
docs citations

127
times ranked

25163
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple endocrine neoplasia type 2: A review. <i>Seminars in Cancer Biology</i> , 2022, 79, 163-179.	9.6	32
2	Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, 8.	1.9	7
3	The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2342-2351.	6.4	6
4	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). <i>Journal of Clinical Oncology</i> , 2022, 40, 1870-1878.	1.6	29
5	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	2.8	102
6	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	2.8	92
7	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
8	Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general population. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 946-954.	3.3	4
9	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
10	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	1.9	21
11	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. <i>Cancers</i> , 2021, 13, 5550.	3.7	4
12	Immunotherapy in Patients with mCRC. , 2021, , 183-186.		0
13	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
14	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154
15	Response to: Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. <i>European Journal of Cancer</i> , 2020, 140, 154-157.	2.8	1
16	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2591.	3.7	8
17	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	2.8	13
18	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2773-2781.	1.6	33
20	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
21	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
22	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics “ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
23	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020, 577, 561-565.	27.8	1,209
24	Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. <i>European Journal of Cancer</i> , 2020, 131, 100-103.	2.8	4
25	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	1.9	19
26	Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’™ and Clinicians’™ Experiences. <i>Journal of Medical Internet Research</i> , 2020, 22, e14896.	4.3	24
27	The real-world outcome of metastatic melanoma: Unknown primary vs</i>. known cutaneous. <i>International Journal of Cancer</i> , 2019, 145, 3173-3174.	5.1	9
28	Diagnosis and treatment of basal cell carcinoma: European consensus“based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	2.8	345
29	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	3.7	37
30	Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. <i>European Journal of Cancer</i> , 2019, 121, 74-84.	2.8	3
31	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	1.9	17
32	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	2.8	27
33	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	27.0	2,484
34	High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. <i>European Journal of Cancer</i> , 2019, 115, 61-67.	2.8	11
35	The real-world impact of modern treatments on the survival of patients with metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 108, 25-32.	2.8	47
36	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1424674.	4.6	43

#	ARTICLE	IF	CITATIONS
37	Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites. <i>Hypertension</i> , 2018, 71, 473-480.	2.7	10
38	Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 77.	2.4	14
39	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018, 28, 333-340.	1.2	13
40	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6021-6021.	1.6	7
41	The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. <i>European Journal of Cancer</i> , 2017, 74, 89-95.	2.8	77
42	Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration. <i>American Journal of Dermatopathology</i> , 2017, 39, 672-678.	0.6	7
43	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	10.7	428
44	Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid Tissue. <i>European Thyroid Journal</i> , 2017, 6, 276-280.	2.4	8
45	Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. <i>Acta OncolÅ³gica</i> , 2017, 56, 109-110.	1.8	9
46	Stabilization of circulating thyroglobulin mRNA transcripts in patients treated for differentiated thyroid carcinoma. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 558-566.	1.6	5
47	Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. <i>Melanoma Research</i> , 2016, 26, 367-376.	1.2	22
48	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€œ Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	2.8	330
49	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	27.0	1,140
50	Trends in melanoma in the elderly in Denmark, 1980â€“2012. <i>Acta OncolÅ³gica</i> , 2016, 55, 52-58.	1.8	6
51	The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. <i>EJNMMI Research</i> , 2016, 6, 73.	2.5	10
52	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2016, 5, 187-194.	2.4	11
53	Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication. <i>Anticancer Research</i> , 2016, 36, 749-56.	1.1	10
54	Consumption of the Epidermis. <i>American Journal of Dermatopathology</i> , 2015, 37, 841-845.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
56	Papillary Thyroid Carcinoma in Denmark, 1996–2008: Outcome and Evaluation of Established Prognostic Scoring Systems in a Prospective National Cohort. <i>Thyroid</i> , 2015, 25, 78-84.	4.5	59
57	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 1989-2007.	2.8	404
58	Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 349-355.	4.2	12
59	Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 769-776.	4.2	3
60	Melanoma Early Detection and Awareness. <i>American Journal of Therapeutics</i> , 2015, 22, 37-43.	0.9	10
61	MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. <i>Melanoma Research</i> , 2015, 25, 113-118.	1.2	11
62	Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 44-53.	0.9	11
63	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	2.8	320
64	Benefit of adjuvant interferon alfa-2b (IFN- β) therapy in melanoma patients with high serum MMP-8 levels. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 173-180.	4.2	9
65	Prognostic Stratification of Ulcerated Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 845-856.	0.7	28
66	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2014, 384, 319-328.	13.7	1,295
67	Completeness and validity in a national clinical thyroid cancer database: DATHYRCA. <i>Cancer Epidemiology</i> , 2014, 38, 633-637.	1.9	20
68	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6060-6060.	1.6	14
69	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6061-6061.	1.6	6
70	Papillary thyroid carcinoma in Denmark 1996–2008: An investigation of changes in incidence. <i>Cancer Epidemiology</i> , 2013, 37, e1-e6.	1.9	35
71	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e23288.	4.6	25
72	Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. <i>Acta OncolÅ³gica</i> , 2013, 52, 1086-1093.	1.8	11

#	ARTICLE	IF	CITATIONS
73	Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. <i>Melanoma Research</i> , 2013, 23, 21-26.	1.2	11
74	Papillary Thyroid Microcarcinoma in Denmark 1996–2008: A National Study of Epidemiology and Clinical Significance. <i>Thyroid</i> , 2013, 23, 1159-1164.	4.5	57
75	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837.	1.6	88
76	A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer. <i>European Thyroid Journal</i> , 2013, 2, 195-202.	2.4	16
77	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	1.6	23
78	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	1.6	48
79	Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 287-293.	1.2	48
80	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 555-567.	7.0	267
81	Interleukin-6 and melanoma. <i>Melanoma Research</i> , 2012, 22, 327-333.	1.2	70
82	Prestimulation with Recombinant Human Thyrotropin (rhTSH) Improves the Long-Term Outcome of Radioiodine Therapy for Multinodular Nontoxic Goiter. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2653-2660.	3.6	36
83	CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 299-303.	0.7	23
84	Large Discrepancy in the Results of Sensitive Measurements of Thyroglobulin Antibodies in the Follow-Up on Thyroid Cancer: A Diagnostic Dilemma. <i>European Thyroid Journal</i> , 2012, 1, 193-197.	2.4	9
85	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 897-905.	10.7	331
86	Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8545-8545.	1.6	0
87	Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 144-152.	10.7	93
88	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204.	4.4	500
89	Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Nodular Goiter Allows Major Reduction of the Radiation Burden with Retained Efficacy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3719-3725.	3.6	43
90	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3794-3801.	1.6	337

#	ARTICLE	IF	CITATIONS
91	Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon. <i>Journal of the National Cancer Institute</i> , 2009, 101, 869-877.	6.3	72
92	Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 31-42.	27.0	446
93	Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?. <i>Acta Oncologica</i> , 2008, 47, 451-457.	1.8	22
94	A phase II study of thalidomide in patients with brain metastases from malignant melanoma. <i>Acta Oncologica</i> , 2008, 47, 1526-1530.	1.8	21
95	Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Large Nodular Goiters Facilitates Tracheal Decompression and Improves Inspiration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3981-3984.	3.6	48
96	A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. <i>Acta Oncologica</i> , 2007, 46, 374-377.	1.8	2
97	Improvement of Goiter Volume Reduction after 0.3 mg Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with a Very Large Goiter: A Double-Blinded, Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3424-3428.	3.6	82
98	The Prognostic Role of Blood Lymphocyte Subset Distribution in Patients With Resected High-risk Primary or Regionally Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2007, 30, 773-779.	2.4	11
99	Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 2007, 85, 24-28.	0.6	41
100	The Danish national guidelines for treatment of oral squamous cell carcinoma. <i>Acta Oncologica</i> , 2006, 45, 294-299.	1.8	28
101	Duration of symptoms: Impact on outcome of radiotherapy in glottic cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 789-794.	0.8	33
102	Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5117-5125.	1.6	114
103	A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma. <i>Radiotherapy and Oncology</i> , 2005, 77, 143-147.	0.6	22
104	Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: A national survey from DAHANCA. <i>Head and Neck</i> , 2003, 25, 711-716.	2.0	88
105	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. <i>Lancet, The</i> , 2003, 362, 933-940.	13.7	626
106	Cancer of the Larynx: Treatment Results after Primary Radiotherapy with Salvage Surgery in a Series of 1005 Patients. <i>Acta Oncologica</i> , 2002, 41, 69-76.	1.8	66
107	Does Radioiodine Therapy Have an Equal Effect on Substernal and Cervical Goiter Volumes? Evaluation by Magnetic Resonance Imaging. <i>Thyroid</i> , 2002, 12, 313-317.	4.5	37
108	Hypopharyngeal Cancer: Results of Treatment Based on Radiation Therapy and Salvage Surgery. <i>Laryngoscope</i> , 2002, 112, 834-838.	2.0	67

#	ARTICLE	IF	CITATIONS
109	Osteoradionecrosis of the jaws: Clinical characteristics and relation to the field of irradiation. <i>Journal of Oral and Maxillofacial Surgery</i> , 2000, 58, 1088-1093.	1.2	244
110	Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. <i>Breast Cancer Research and Treatment</i> , 2000, 61, 103-110.	2.5	20
111	The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3636-3641.	3.6	102
112	Prognostic Factors in Papillary and Follicular Thyroid Carcinomas. <i>Laryngoscope</i> , 1998, 108, 243-249.	2.0	37
113	A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. <i>Radiotherapy and Oncology</i> , 1998, 46, 135-146.	0.6	523
114	Lymph Node Metastases from Laryngeal and Pharyngeal Carcinomas: Calculation of Burden of Metastasis and its Impact on Prognosis. <i>Acta Oncologica</i> , 1998, 37, 489-493.	1.8	50
115	Osseointegrated Implants for Prosthetic Rehabilitation after Treatment of Cancer of the Oral Cavity. <i>Acta Oncologica</i> , 1997, 36, 37-40.	1.8	32
116	Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. <i>Radiotherapy and Oncology</i> , 1997, 43, 47-51.	0.6	133
117	The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 35, 45-52.	2.3	18
118	The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 439-443.	2.3	7
119	Influence of Late Side-Effects Upon Daily Life After Radiotherapy for Laryngeal and Pharyngeal Cancer. <i>Acta Oncologica</i> , 1994, 33, 487-491.	1.8	102
120	Weekly Oral Idarubicin in Advanced Prostatic Cancer A Phase II Study. <i>Acta Oncologica</i> , 1992, 31, 337-340.	1.8	8
121	High-dose platinum chemotherapy in advanced ovarian cancer: A phase II study. <i>Gynecologic Oncology</i> , 1992, 44, 79-82.	1.4	12
122	Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 63-68.	2.3	36
123	A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 205-210.	2.3	10
124	A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 465-469.	2.3	55
125	Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 627-634.	4.7	25